Companies Virpax Pharmaceuticals, Inc.
Virpax Pharmaceuticals CEO salary & total pay, FY2023: $128K
Virpax Pharmaceuticals (VRPX) CEO salary, fiscal 2023: Gerald Bruce was paid a salary of $38,000 and $128,000 in total compensation. Free brief. Every figure links to the company’s own filing.
Virpax Pharmaceuticals, Inc. no longer files a proxy statement; its last pay data is FY2023.
Gerald Bruce's complete compensation dossier
A PDF and a CSV sent to your email: Gerald Bruce's pay in every fiscal year Virpax Pharmaceuticals, Inc. reported it, line by line, with Gerald Bruce's equity grants and Virpax Pharmaceuticals, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.
See an example →CEO pay, last three years
- $128,000FY2023
CEO total pay was $128,000 in fiscal 2023; the brief holds no earlier figure for this CEO.
FY2023: salary $38,000 · bonus $29,000 · stock awards $0 · option awards $61,000
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Anthony Mack | $445,000 | $0 | $0 | $60,000 | $0 | $0 | $711,000 | $1,216,000 |
| Former Chief Executive Officer, Chairman (3) | ||||||||
| Sheila Mathias | 308,000 | 115,000 | 0 | 75,000 | 0 | 0 | 0 | 498,000 |
| Chief Scientific Officer | ||||||||
| Christopher Chipman | 169,000 | 0 | 0 | 75,000 | 0 | 0 | 247,000 | 491,000 |
| Former Chief Financial Officer (5) | ||||||||
| Vinay Shah | 123,000 | 115,000 | 0 | 86,000 | 0 | 0 | 0 | 324,000 |
| Chief Financial Officer | ||||||||
| Gerald Bruce | 38,000 | 29,000 | 0 | 61,000 | 0 | 0 | 0 | 128,000 |
| Chief Executive Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Anthony Mack | $1,216,000 | $784,000 | — | ↑ +432,000 |
| Sheila Mathias | 498,000 | — | — | — |
| Christopher Chipman | 491,000 | 467,000 | — | ↑ +24,000 |
| Vinay Shah | 324,000 | — | — | — |
| Gerald Bruce | 128,000 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Board and Compensation Committee annually review executive compensation to align pay practices with companies of similar size and development stage. Compensation is designed to be commensurate with the Company's and management's performance, utilizing a mix of base salary, discretionary annual cash bonuses, and equity awards.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2023
| Executive | Award | Exercisable | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|---|
| Anthony Mack | Option | 2,022 | — | 98.9 | — |
| Anthony Mack | Option | 4,045 | — | 98.9 | — |
| Anthony Mack | Option | 3,333 | — | 46.2 | — |
| Anthony Mack | Option | 2,022 | — | 23.4 | — |
| Gerald Bruce | Option | 1,516 | — | 98.9 | — |
| Gerald Bruce | Option | 3,000 | — | 46.2 | — |
| Gerald Bruce | Option | 6,000 | — | 17.6 | — |
| Gerald Bruce | Option | 10,000 | — | 7.3 | — |
| Sheila Mathias | Option | 1,667 | 833 | 46.2 | — |
| Sheila Mathias | Option | 2,023 | 4,045 | 21.3 | — |
| Sheila Mathias | Option | — | 11,200 | 7.88 | — |
| Vinay Shah | Option | — | 10,000 | 9.9 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Jeffrey Gudin, MDEmployee director | $158,000 | — | $34,000 | — | — | $192,000 |
| Eric Floyd, PhDIndependent · Board Chair · Compensation (Chair) · Nominating and Corporate Governance · Science and Technology (Chair) | 55,000 | — | 23,850 | — | — | 78,850 |
| Thani Jambulingam, PhDIndependent · Audit · Compensation · Nominating and Corporate Governance (Chair) · Science and Technology | 55,000 | — | 21,200 | — | — | 76,200 |
| Jerrold Sendrow, CFPIndependent · Audit (Chair) · Compensation · Nominating and Corporate Governance | 55,000 | — | 18,550 | — | — | 73,550 |
| Michael F. DubinIndependent · Audit | 55,000 | — | 10,600 | — | — | 65,600 |
| Barbara A. Ruskin, PhD, J.DIndependent · Audit · Nominating and Corporate Governance · Science and Technology | 46,000 | — | 17,750 | — | — | 63,750 |
| Vanila M. Singh, MDIndependent · Science and Technology | 55,000 | — | 7,950 | — | — | 62,950 |
| Gerald BruceEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $60,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | — |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $479,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $479,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Virpax Pharmaceuticals as a peer
Companies that benchmark against VRPX
The list of companies that name VRPX as a peer is temporarily unavailable — recheck shortly.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Virpax Pharmaceuticals, Inc. | 2023 | Gerald Bruce | $38,000 | $0 | $61,000 | $0 | $128,000 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-01-15 | — | — | — | — | — |
| 2024 | 2024-07-29 | — | — | — | — | — |
| 2023 | 2023-12-28 | — | — | — | — | — |
| 2022 | 2022-07-25 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-01-15 | —a |
| 2024 | 2024-07-29 | —b |
| 2023 | 2023-12-28 | —c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jatinder Dhaliwal | Director | 2024-07-05 | A | 2,500 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Gary L. Herman | Director | 2024-07-05 | A | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Katharyn Field | Director | 2024-07-05 | A | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (22 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Anthony Mack. 10-K, filed 2024-06-12. Section “Summary Compensation Table” · page 21. As printed: 1,216,000. View filing ↗
- Section 01, Sheila Mathias. 10-K, filed 2024-06-12. Section “Summary Compensation Table” · page 21. As printed: 498,000. View filing ↗
- Section 01, Christopher Chipman. 10-K, filed 2024-06-12. Section “Summary Compensation Table” · page 21. As printed: 491,000. View filing ↗
- Section 01, Vinay Shah. 10-K, filed 2024-06-12. Section “Summary Compensation Table” · page 21. As printed: 324,000. View filing ↗
- Section 01, Gerald Bruce. 10-K, filed 2024-06-12. Section “Summary Compensation Table” · page 21. As printed: 128,000. View filing ↗
- Section 08, Jeffrey Gudin, MD. 10-K, filed 2024-06-12. Section “Director Compensation”. As printed: 192,000. View filing ↗
- Section 08, Eric Floyd, PhD. 10-K, filed 2024-06-12. Section “Director Compensation”. As printed: 78,850. View filing ↗
- Section 08, Thani Jambulingam, PhD. 10-K, filed 2024-06-12. Section “Director Compensation”. As printed: 76,200. View filing ↗
- Section 08, Jerrold Sendrow, CFP. 10-K, filed 2024-06-12. Section “Director Compensation”. As printed: 73,550. View filing ↗
- Section 08, Michael F. Dubin. 10-K, filed 2024-06-12. Section “Director Compensation”. As printed: 65,600. View filing ↗
- Section 08, Barbara A. Ruskin, PhD, J.D. 10-K, filed 2024-06-12. Section “Director Compensation”. As printed: 63,750. View filing ↗
- Section 08, Vanila M. Singh, MD. 10-K, filed 2024-06-12. Section “Director Compensation”. As printed: 62,950. View filing ↗
- Section 08, Gerald Bruce. 10-K, filed 2024-06-12. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Jatinder Dhaliwal 2024-07-05. Form 4, filed 2024-07-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gary L. Herman 2024-07-05. Form 4, filed 2024-07-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katharyn Field 2024-07-05. Form 4, filed 2024-07-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-01-15. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-07-30. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-12-29. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 479,000 + equity 0 + all other 0 = 479,000, summed across the director compensation table rows.
- Virpax Pharmaceuticals, Inc. (subject), Section 10b CEO total. 10-K, filed 2024-06-12. CEO total compensation as printed in Virpax Pharmaceuticals, Inc.'s own proxy. As printed: 128,000. View filing ↗